

April 8, 2024

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

Dear Sir,

Sub: Summary of Proceedings of 44th Annual General Meeting

Ref: Scrip code –BSE: 506820, NSE: ASTRAZEN

In furtherance to your email dated April 6, 2024 and the enclosed summary of proceedings of 44th Annual General Meeting held on August 14, 2023, we wish to inform that the 44th Annual General Meeting commenced at 3:00 P.M. and concluded at 4:45 P.M. (IST).

Kindly take same on record.

For AstraZeneca Pharma India Limited

Manasa. R
Company Secretary



August 15, 2023

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir,

Sub: Summary of Proceedings of 44th Annual General Meeting
Ref: Scrip code –BSE: 506820, NSE: ASTRAZEN

Pursuant to the provisions of Regulation 30 read with Part A of Schedule III to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the following business were transacted at the 44th Annual General Meeting (AGM) of the Company held on August 14, 2023 at 3.00 P.M. through Video Conferencing/Other Audio Visual Means:

1. Adoption of Financial Statements for the financial year ended March 31, 2023 and the Reports of the Board of Directors and Auditors thereon.
2. Declaration of dividend of Rs. 16/- per Equity Share.
3. Appointment of Ms. Weiyang Sarah Wang (DIN: 08369289), Non-Executive Director who retires by rotation, and being eligible, offers herself for re-appointment.
4. Consideration of material Related Party Transactions with AstraZeneca UK Limited for an amount not exceeding in aggregate Rs. 600 crore for the period from 44th Annual General Meeting until the 45th Annual General Meeting.
5. Consideration of material Related Party Transactions with AstraZeneca AB, Sweden for an amount not exceeding in aggregate Rs. 250 crore for the period from 44th Annual General Meeting until the 45th Annual General Meeting.
6. Ratification of Cost Auditor's remuneration.

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628



Kindly note that voting results will be announced upon the receipt of Scrutinizer's Report and will be submitted as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please take same on record.

For AstraZeneca Pharma India Limited

MANAS Digitally signed by
MANASA RAMA
A RAMA Date: 2023.08.15
11:53:21 +05'30'

Manasa. R
Company Secretary

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628